stated that any risk of failure was due to consistency with the biopsy results. I'm sure management was shocked to see the placebo effect since this should have been zero. The good thing is that the preliminary secondary endpoints for the 6 month data clearly shows migalastat works. This combined with the 12 month data we'll see in the 1st qtr will get the program back on track for FDA approval.
I wouldn't be surprised to see positive Pompe data next week & a CC where management can explain the plans going forward. We'll probably be trading over $4 before the end of year.